Alfred Noble Prize

Dr. Mia Talmor Joins the MTF Biologics Board of Directors

Retrieved on: 
Wednesday, March 27, 2024
Research, Surgery, Hospitals, Stem Cells, Other Health, Biotechnology, General Health, Health, Science, Other Science, MTF, Growth, Weill Cornell Medicine, Plastic, Woman, Today (American TV program), The New York Times, NewYork-Presbyterian Hospital, Trustee, Patient, Committee, Female, Breast, Rockefeller University, Plastic surgery, Aesthetic Plastic Surgery, Castle Connolly Medical, American College, Publication, American College of Surgeons, Society, Hospital, CBS, Division, Alfred Noble Prize, Bangladesh Technical Education Board, Multimedia, Education Committee, Public key certificate, Dentistry

MTF Biologics , a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing the science of tissue transplantation, has announced the appointment of Mia Talmor, MD , to the MTF Biologics Board of Directors.

Key Points: 
  • MTF Biologics , a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing the science of tissue transplantation, has announced the appointment of Mia Talmor, MD , to the MTF Biologics Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20240327225210/en/
    Dr. Mia Talmor, Professor of Clinical Surgery at The Weill Cornell Medical School and attending surgeon at New York Presbyterian Hospital, has joined the MTF Biologics Board of Directors.
  • (Photo: Business Wire)
    “We are honored to welcome Dr. Talmor to the MTF Board,” said William W. Tomford, MD, Chairman of the MTF Biologics Board of Directors.
  • Talmor brings a legacy of groundbreaking achievements in plastic surgery,” said Joe Yaccarino, MTF Biologics’ President and CEO.

"Global Boiling" Rejected by Many - Widening Gap in Scientific Opinion says Friends of Science Society

Retrieved on: 
Friday, August 25, 2023
Risk, Science Society of China, Intergovernmental Panel on Climate Change, Nature, Interview, Metal, AR6, Climate change, Wildfire, Alfred Noble Prize, Policy, AESO, AB, Smith, Guterres, Language, NBC, Wind, Friends, IPCC, UN, Natural gas, Physics, Deep Decarbonization Pathways Project, NetZero, Die Welt, Reticle, Renewable energy, Seaweed

CALGARY, AB, Aug. 24, 2023 /PRNewswire-PRWeb/ -- July's heat caused UN Sec. Gen. Antonio Guterres to claim we are now in the era of 'global boiling,' a view not held by everyone says Friends of Science Society. Cases in point NBC reported" for saying things like "more people are dying of bad climate change policies than they are of actual climate change." Ramaswamy is a bio-tech entrepreneur and author of "Woke, Inc" which denounces corporate social 'justice.'

Key Points: 
  • Gen. Guterres declared we are in an era of 'global boiling,' Vivek Ramaswamy, US Presidential candidate disputes climate change agenda, says Friends of Science Society.
  • Gen. Antonio Guterres to claim we are now in the era of ' global boiling ,' a view not held by everyone says Friends of Science Society.
  • Friends of Science Society's report " Clean Electricity Standard: Delusion vs Reality " outlines the impacts and challenges of attempting to reach NetZero goals and decarbonize Canada.
  • China has a publicly stated bid to become the globally dominant power by 2049, as reported by Bloomberg Oct. 26, 2022.

Dr. Andres Betts Joins Pain Medicine Associates - Mission Viejo, California

Retrieved on: 
Tuesday, July 18, 2023
Pain disorder, University, Long Beach, California, Cranial nerves, Critical Care Medicine (journal), Skiing, Sciatica, Alfred Noble Prize, Spine, Radiofrequency ablation, Suite, Piriformis syndrome, PMA, University of California, Irvine Medical Center, Patient, Physician, Pain Clinic, Associate, Mountaineering, Pain, Diagnosis, Sacral fracture, Bone fracture, General surgery, Nursing, Dentistry, Anesthesiology, Medicine

MISSION VIEJO, Calif., July 18, 2023 /PRNewswire-PRWeb/ -- Pain Medicine Associates (PMA) is pleased to announce that interventional pain management specialist Andres Betts, M.D., has joined the company's Mission Viejo, California pain management practice. He began seeing patients on July 3rd at the office, located at 26137 La Paz Rd, Suite 140, Mission Viejo, CA 92691.

Key Points: 
  • MISSION VIEJO, Calif., July 18, 2023 /PRNewswire-PRWeb/ -- Pain Medicine Associates (PMA) is pleased to announce that interventional pain management specialist Andres Betts, M.D., has joined the company's Mission Viejo, California pain management practice.
  • He began seeing patients on July 3rd at the office, located at 26137 La Paz Rd, Suite 140, Mission Viejo, CA 92691.
  • Dr. Betts is an innovative, board-certified, fellowship trained interventional pain management physician that specializes in the diagnosis and treatment of pain disorders.
  • He founded the Pain Clinic in Bellingham, Washington and Pain MD Medical Associates in San Clemente, California.

Malala Yousafzai's Parents Visit Power of Children Exhibit and Leave with A Heart Full of Pride & Donate More Precious Artifacts to Help Tell Story of Daughter's Legacy

Retrieved on: 
Thursday, March 23, 2023
Cherokee heritage groups, Lighting, Nobel Prize, Ruby Bridges, LLP, Heritage, The, Education, Life, Ice, Alfred Noble Prize, Tears, Light, Hope, Flower, Human, Old National Bank, History, Taliban, Yusufzai, The Power of Children, Student, Portrait, The Children's Museum of Indianapolis, Museum, Nobel, Artifact, Female, Malala's Magic Pencil, Entertainment, Toy, Pakistanis, Malala Yousafzai

"I was very moved by the lighting show because it summarizes the story so powerfully," said Ziauddin Yousafzai. "I cried a little bit – it moved me to tears; also, the performer and the way she performed and she presented the story – that was also incredibly powerful!." Yousafzai went on to say how every part of the story is beautiful and he appreciates how much work went into making the experience authentic, "I was very impressed to see how the house, the doors and the flowers – how that particular plant has grown… then our home and the neighbors and in the background – the mountains. You feel like you are standing in Mingora and Butkara and in the street where we lived." Yousafzai continued, "So that feeling - it's so beautiful – so you see - yes, this is my story, this is my valley's story, this is my country's story. This is our people's story -- thank you for documenting it for the people."

Key Points: 
  • For the first time, Ziauddin and his wife Toor Pekai Yousafzai saw the exhibit with their own eyes.
  • Those eyes swelled up with tears as they relived what happened to their daughter and their hearts swelled up with pride acknowledging what she's accomplished.
  • Since that time, she has endured multiple surgeries and continues to fight for girls to receive a proper education.
  • The Yousafzai family donated additional artifacts and loaned a traditional, special baby ring gifted to Malala from her maternal grandmother.

Clarivate and the Chinese Academy of Sciences Release Annual Joint Report to Identify 165 Research Fronts

Retrieved on: 
Tuesday, January 3, 2023
COVID-19 vaccine, Health care, Chinese Academy of Sciences, Clarivate, Education, NYSE, Professional services, Literature, COVID, Partnership, GW190814, COVID-19, Face, Attention, Web of Science, S&T, Alfred Noble Prize, Invention, Final good, Database, ESI, Social, Research, CAS, Cataloging, Pharmaceutical industry, Management, Renewable energy, Science

LONDON, Jan. 3, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, and the Chinese Academy of Sciences (CAS) today released Research Fronts 2022, their ninth annual collaborative report. The report identifies significant areas in the world of sciences and social sciences as to where the scientific community is focusing its attention, including several COVID-related fronts and areas mirrored by the research fields of Noble Prize in recent years.

Key Points: 
  • The 2022 report starts with 12,610 Research Fronts in the ESI™ from 2016 to 2021 and aims to discover which Research Fronts were most active or developing most rapidly.
  • This year's report identified 165 Research Fronts, including 110 'hot' and 55 'emerging' fronts spanning in 11 broad areas.
  • Experts at CAS analyzed and interpreted all the Research Fronts to further highlight 32 key Research Fronts and one key Research Front group.
  • In conjunction with the Research Fronts 2022 report, Clarivate and CAS also published 2022 Research Fronts: Active Fields, Leading Countries to examine and compare national performance across the 165 Research Fronts.

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

Retrieved on: 
Tuesday, October 18, 2022
Therapy, Therapeutic index, Biotechnology, Technology, Kyowa Hakko Kirin, Alfred Noble Prize, Cristal, COGS, Aravis, Fluorophore, ADC, Moa, Nanoparticle, Emergence, Click chemistry, Peptide, Control, Nucleotide, Fine chemical, Pharmaceutical industry, Chemistry, Synaffix

Under the terms of the agreement, Synaffix will obtain exclusive rights to theCliCr technology, to combine with its proprietary ADC platform technology.

Key Points: 
  • Under the terms of the agreement, Synaffix will obtain exclusive rights to theCliCr technology, to combine with its proprietary ADC platform technology.
  • Floris van Delft, Chief Scientific Officer of Synaffix, said:"We areimpressedby the properties ofCliCr,which clearly demonstrate best-in-class potential as chemistry formetal-free clickconjugationwith azides.
  • Cristianne Rijcken, Chief Scientific Officer of Cristal Therapeutics stated: "We are emboldened by this license agreement with Synaffix, a leading provider of ADC technology, as it underscores the potential of our unique CliCr technology.
  • The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics and Emergence Therapeutics.

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

Retrieved on: 
Tuesday, October 18, 2022
Therapy, Therapeutic index, Biotechnology, Technology, Kyowa Hakko Kirin, Alfred Noble Prize, Cristal, COGS, Aravis, Fluorophore, ADC, Moa, Nanoparticle, Emergence, Click chemistry, Peptide, Control, Nucleotide, Fine chemical, Pharmaceutical industry, Chemistry, Synaffix

Under the terms of the agreement, Synaffix will obtain exclusive rights to theCliCr technology, to combine with its proprietary ADC platform technology.

Key Points: 
  • Under the terms of the agreement, Synaffix will obtain exclusive rights to theCliCr technology, to combine with its proprietary ADC platform technology.
  • Floris van Delft, Chief Scientific Officer of Synaffix, said:"We areimpressedby the properties ofCliCr,which clearly demonstrate best-in-class potential as chemistry formetal-free clickconjugationwith azides.
  • Cristianne Rijcken, Chief Scientific Officer of Cristal Therapeutics stated: "We are emboldened by this license agreement with Synaffix, a leading provider of ADC technology, as it underscores the potential of our unique CliCr technology.
  • The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics and Emergence Therapeutics.

Researchers Discover New Model for "Global" DNA Repair

Retrieved on: 
Wednesday, March 30, 2022
Cell, Face, New York University Grossman School of Medicine, NYU Langone Health, UvrABC endonuclease, NYU, State Key Laboratories, DNA, Biochemistry, Death, DNA repair, Synthetic biology, Rho, Bacteria, Alfred Noble Prize, GGR, National Natural Science Foundation of China, Pharmacology, Doctor of Philosophy, Ecology, Plant physiology, TCR, Institute of Biophysics, Chinese Academy of Sciences, RNA, National Institutes of Health, Nature Communications, Medicine, Howard Hughes Medical Institute, Genome, Programmer, Technology, National Medal of Technology and Innovation, NIH, National, Institute, Ageing, Mass spectrometry, Gene, Department, Enzyme, Exploratory Science Center, Swiss National Science Foundation, NER, Physiology, Shakne Epshtein, Vaccine, Pharmaceutical industry, Nature, Evgeny Nudler

NEW YORK, March 30, 2022 /PRNewswire/ -- Two studies provide a radically new picture of how bacterial cells continually repair damaged sections (lesions) in their DNA.

Key Points: 
  • Given that damaged DNA can result in detrimental DNA code changes (mutations) and death, cells evolved to have DNA repair machineries.
  • Widely accepted work, including studies that led to a 2015 Noble Prize , had argued that TCR played a relatively small role in repair because it relied on a putative TCR factor that made only a marginal contribution to DNA repair.
  • A parallel process, global genome repair (GGR), was assumed to scan and fix most of DNA independent of transcription.
  • Both processes were thought to set the stage for nucleotide excision repair (NER), in which a damaged stretch of DNA was snipped out and replaced by an accurate copy.

Prestigious Unicorn of Tomorrow Opens Registration for 'The Ultimate Startup Contest'

Retrieved on: 
Monday, November 22, 2021
Emirates (airline), Alfred Noble Prize, UN, GLOBE, Interest, Time, Unicorn, Growth, Creative industries

Unicorn of Tomorrow, based in Stockholm, bills itself as "The Ultimate Startup Contest."

Key Points: 
  • Unicorn of Tomorrow, based in Stockholm, bills itself as "The Ultimate Startup Contest."
  • The startup contestant chosen by each country will be invited to the Unicorn of Tomorrow grand finale event - the next one taking place Oct. 1, 2022 in Stockholm, Sweden.
  • "Sweden is the birth country of the Noble Prize and the Polar Music Prize," says Unicorn of Tomorrow founder Richard Burstrom.
  • Unicorn of Tomorrow works as an accelerator for innovation and for fresh business ideas growth."